November 8, 2019 03:08 PM ESTUpdated January 24, 05:52 AM
R&D

With key test still loom­ing, Cel­gene and Ac­celeron nab FDA okay for be­ta-tha­lassemia med

Jason Mast

Editor

While pric­ing con­cerns con­tin­ue to cloud the fu­ture of blue­bird bio’s gene ther­a­py fix, the FDA has giv­en its okay for Cel­gene and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

RFK Jr. de­fends HHS staff cuts, re­or­ga­ni­za­tion plans in House, Sen­ate hear­ings

FDA gives Ab­b­Vie ac­cel­er­at­ed ap­proval for an­ti­body-drug con­ju­gate in lung can­cer

RFK Jr. says his opin­ions of vac­cines are ‘ir­rel­e­vant.’ For­mer FDA chief Califf dis­agrees

Ab­b­Vie dou­bles down on siR­NA with $335M up­front bet on ADARx

GSK to pay $1.2B up­front to snag Boston Phar­ma’s mid-stage MASH hope

Sanofi touts $20B in­vest­ment in US over five years

A service from the Financial Times